Breztri Dosing
Breztri is NOT indicated for asthma—it is FDA-approved exclusively for COPD maintenance treatment. 1
FDA-Approved Dosing (COPD Only)
The recommended dose is 2 inhalations twice daily (morning and evening), delivering budesonide 320 mcg, glycopyrrolate 18 mcg, and formoterol fumarate 9.6 mcg per day (160 mcg/9 mcg/4.8 mcg per inhalation). 1
Key Administration Details:
- Do not exceed 2 inhalations twice daily
- Rinse mouth with water after each use (without swallowing) to reduce local corticosteroid side effects
- Prime before first use: Release 4 sprays into the air (away from face), shaking well before each spray
- Re-prime if: Not used for >7 days, dropped, or after weekly rinsing (2 sprays)
- Discard when: Dose counter pointer reaches zero (red zone) 1
Critical Contraindication for Asthma
Breztri is contraindicated for asthma treatment. 1 The FDA label explicitly warns that long-acting beta2-agonists (LABAs) as monotherapy—or in combinations not specifically studied for asthma—increase the risk of asthma-related death, hospitalization, and intubation. 1
Why This Matters:
- The triple combination of budesonide/glycopyrrolate/formoterol has not been studied in asthma patients
- Safety and efficacy data exist only for COPD populations
- While individual components (ICS/LABA combinations like budesonide/formoterol) are used in asthma, the addition of glycopyrrolate (a LAMA) in this specific formulation lacks asthma trial data
Alternative for Asthma Patients
If you're seeking similar therapy for asthma, consider:
Budesonide/formoterol combinations (without the LAMA component) are appropriate for asthma and can be used in SMART (Single Maintenance and Reliever Therapy) regimens for patients ≥12 years with moderate-to-severe asthma. 2, 3
- Maintenance dosing: 1-2 inhalations twice daily (budesonide 160 mcg/formoterol 4.5 mcg per inhalation)
- As-needed reliever: Additional inhalations for symptom relief (maximum 12 total inhalations/day in adults) 3
- This approach reduces severe exacerbations while lowering overall ICS exposure compared to fixed-dose regimens 4
Common Pitfall:
Clinicians sometimes confuse triple therapy formulations approved for COPD with ICS/LABA combinations appropriate for asthma. Always verify the specific indication—using Breztri off-label for asthma lacks safety data and violates FDA guidance on LABA use in asthma without established ICS/LABA combination evidence. 1